text: PURPOSE: Dasatinib (<< BMS-354825 >>), a potent oral multi-targeted kinase inhibitor against SRC and [[ BCR ]]-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance.